Mineralys Therapeutics (MLYS) Preferred Stock Liabilities (2022)
Mineralys Therapeutics (MLYS) reported Preferred Stock Liabilities of $117.7 million for Q4 2022, little changed sequentially from $117.7 million in Q3 2022.
Mineralys Therapeutics (MLYS) Preferred Stock Liabilities (2022) Analysis & Trends
Mineralys Therapeutics (MLYS) has 1 years of Preferred Stock Liabilities data on file, last reported at $117.7 million in Q4 2022.
- For the quarter ending Q4 2022, Preferred Stock Liabilities changed N/A year-over-year to $117.7 million; the trailing twelve-month figure through Dec 2022 stood at $117.7 million (changed N/A YoY), and the FY2022 full-year result was $117.7 million, changed N/A from the prior year.
- Preferred Stock Liabilities steadied at $117.7 million in Q4 2022, from $117.7 million in the prior quarter.
- In the past five years, Preferred Stock Liabilities ranged from a high of $117.7 million in Q2 2022 to a low of $41.0 million in Q1 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Mineralys Therapeutics | 2.24 Bn | 2.24 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 117.66 Mn |
| Sep 30, 2022 | 117.66 Mn |
| Jun 30, 2022 | 117.66 Mn |
| Mar 31, 2022 | 40.99 Mn |